• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

LX7101 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755128

LX7101 is an effective inhibitor of LIMK and ROCK2 (IC50: 24, 1.6, and 10nM for LIMK1, LIMK2, and ROCK2, respectively). It also inhibits PKA (IC50 More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
LX7101, Inhibitor
Full Product Name
LX7101
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
451.52
Solubility
DMSO: 150mg/mL (332.21mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C23H29N7O3
SMILES
NCC1(C(NC2=CC(OC(N(C)C)=O)=CC=C2)=O)CCN(C3=C4C(NC=C4C)=NC=N3)CC1
CAS Number
1192189-69-7
Target & IC50
ROCK2: ic50 10nM
LIMK2: ic50 1.6nM
LIMK1: ic50 24nM
PKA: ic50 1nM
In Vitro
Topical doses of LX-7101 are evaluated for tolerability in the eyes of mice, rats, and rabbits. It is well tolerated at doses up to 0.5% in non-GLP single-dose studies. LX-7101 is advanced to Phase-I clinical trials as intraocular pressure (IOP)-lowering agent for the treatment of glaucoma. LX-7101 shows a significant IOP reduction at time points ranging from 1 h to 6 h post-administration in rabbits[1]. LX-7101 (5%) achieved an additional reduction of IOP (5.0mMHg total reduction) compared to the 0.1% formulation. It also demonstrated a long duration of action, in the mouse IOP assay, with IOP not returning to baseline until more than 8 h postdose[2].

Structure of LX7101, inhibitor

LX7101 Inhibitor – Cat# MBS5755128

Product References and Citations for LX7101, inhibitor

Boland S, et al. Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorganic & Medicinal Chemistry Letters (2015), 25(18), 4005-4010.
Boland S, et al. Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorganic & Medicinal Chemistry Letters (2015), 25(18), 4005-4010.
Harrison BA, et al. Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the treatment,of Glaucoma. ACS Medicinal Chemistry Letters (2015), 6(1), 84-88.
Harrison BA, et al. Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the treatment,of Glaucoma. ACS Medicinal Chemistry Letters (2015), 6(1), 84-88.

Other Notes

Small volumes of LX7101, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for LX7101 purchase

MBS5755128 is an inhibitor targeting LX7101.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000